Gold prices bounce off 3-week lows; demand likely longer term
Kim Hyong, the Chief Medical (TASE:BLWV) Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently sold a significant portion of the company’s stock. The healthcare company, currently valued at $2.87 billion, has demonstrated remarkable performance with a 176% return over the past year, according to InvestingPro data. According to a recent SEC filing, Hyong sold a total of 21,574 shares on March 7, 2025. The transactions, which were executed under a pre-established Rule 10b5-1 trading plan, amounted to a total value of approximately $324,927.
The shares were sold at prices ranging from $14.60 to $15.70 per share. Following these transactions, Hyong holds 486,302 shares of Alignment Healthcare. This sale represents a strategic move under the trading plan adopted on September 5, 2024.
In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16 compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. Additionally, for the full year 2024, Alignment Healthcare achieved a total revenue of $2.7 billion, marking a 48% increase year-over-year. The company also achieved its first year of adjusted EBITDA profitability, a significant milestone. Analyst firms Piper Sandler and Raymond (NSE:RYMD) James have shown confidence in Alignment Healthcare’s future. Piper Sandler raised its price target to $21, maintaining an Overweight rating, while Raymond James increased its target to $19, reiterating a Strong Buy rating. Both firms highlighted Alignment Healthcare’s strong performance and strategic growth potential, especially its effective "flywheel" approach and membership growth. Looking ahead, the company has issued revenue guidance for 2025, projecting figures between $3.72 billion and $3.78 billion, indicating a 40% year-over-year growth at the midpoint.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.